Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.47 |
| ▸ | GAPDH | P04406 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28345168 | 0.98 | FFAR4 (0.55) | FFAR4FFAR1TSHRNFKB1GPR84 | |
| SCHEMBL6514004 | 0.98 | FFAR4 (0.55) | FFAR4FFAR1TSHRNFKB1GPR84 | |
| SCHEMBL7913952 | 0.98 | FFAR4 (0.55) | FFAR4FFAR1TSHRNFKB1GPR84 | |
| SCHEMBL8687254 | 0.98 | FFAR4 (0.55) | FFAR4FFAR1TSHRNFKB1GPR84 | |
| SCHEMBL4069901 | 0.93 | TSHR (0.50) | FFAR4FFAR1TSHRNFKB1GPR84 | |
| SCHEMBL1085914 | 0.91 | TSHR (0.48) | FFAR4FFAR1TSHRNFKB1GPR84 | |
| SCHEMBL16706242 | 0.89 | TSHR (0.67) | FFAR4FFAR1TSHRNFKB1GPR84 | |
| SCHEMBL11798450 | 0.89 | TSHR (0.67) | FFAR4FFAR1TSHRNFKB1GPR84 | |
| SCHEMBL21530621 | 0.89 | TSHR (0.60) | FFAR4FFAR1TSHRNFKB1GPR84 | |
| SCHEMBL19816345 | 0.89 | TSHR (0.67) | FFAR4FFAR1TSHRNFKB1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116148368-A | Method for detecting various environmental pollutants and oxidative damage markers in urine | 华中科技大学 | 2023-05-23 | — | — | CN | claimed |
| CN-115697395-A | Natural antibodies in prophylaxis and therapy | 瓦努迪斯有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-20100004359-A1 | POLYMERIZED (SUBSTITUTED IMIDAZOLIUM) FOR IMPROVED HANDLING PROPERTIES IN SILICA-REINFORCED RUBBER COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2010-01-07 | — | — | US | claimed |
| US-4714490-A | ALIPHATIC ALDEHYDE | KAO CORPORATION (JP) | 1987-12-22 | — | — | US | claimed |
| US-20260071179-A1 | PRODUCTION METHOD OF NERVE CELLS DAMAGED BY OXIDATIVE STRESS AND APPLICATIONS THEREOF | FUJIFILM CORPORATION (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4682249-A1 | METHOD FOR PRODUCING NERVE CELLS DAMAGED BY OXIDATION STRESS AND APPLICATION THEREOF | FUJIFILM Corporation (JP) | 2026-01-21 | — | — | EP | disclosed |
| CN-119874561-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119798741-A | Vanillin crosslinked polyvinyl alcohol chitosan active packaging film and preparation method and application thereof | 浙江省海洋水产研究所 | 2025-04-11 | — | — | CN | disclosed |
| US-20250090541-A1 | Methods for Treating Neurodegenerative Disorders | PRAETEGO INC | 2025-03-20 | — | — | US | disclosed |
| EP-4514349-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | Praetego Inc (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-113950471-B | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-119118953-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20100031398-A1 | GENES ENCODING CHAVICOL/EUGENOL SYNTHASE FROM THE CREOSOTE BUSH LARREA TRIDENTATA | WASHINGTON STATE UNIVERSITY (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100004359-A1 | POLYMERIZED (SUBSTITUTED IMIDAZOLIUM) FOR IMPROVED HANDLING PROPERTIES IN SILICA-REINFORCED RUBBER COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2046110-A2 | GENES ENCODING CHAVICOL/EUGENOL SYNTHASE FROM THE CREOSOTE BUSH LARREA TRIDENTATA | Washington State University (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080280319-A1 | GSH adducts and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-11-13 | — | — | US | disclosed |
| WO-2008005631-A2 | GENES ENCODING CHAVICOL/EUGENOL SYNTHASE FROM THE CREOSOTE BUSH LARREA TRIDENTATA | WASHINGTON STATE UNIVERSITY (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-1490080-A1 | A PROCESS FOR THE EXTRACTION OF ANTHOCYANINS FROM BLACK RICE AND COMPOSITION THEREOF | Forbes Medi-Tech Inc. (CA) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080084-A1 | A PROCESS FOR THE EXTRACTION OF ANTHOCYANINS FROM BLACK RICE AND COMPOSITION THEREOF | FORBES MEDI-TECH INC. (CA) | 2003-10-02 | — | — | WO | disclosed |
| US-4714490-A | ALIPHATIC ALDEHYDE | KAO CORPORATION (JP) | 1987-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280319-A1 | GSH adducts and uses thereof | GSTA2, GSTA1, GSTM2 | FFAR4 3257/4885FFAR1 3198/4885TSHR 3057/4885 |
| US-20100031398-A1 | GENES ENCODING CHAVICOL/EUGENOL SYNTHASE FROM THE CREOSOTE BUSH LARREA TRIDENTATA | CNOT1, CRAT, LRAT | FFAR4 2347/4885FFAR1 2038/4885TSHR 3703/4885 |
| US-20260071179-A1 | PRODUCTION METHOD OF NERVE CELLS DAMAGED BY OXIDATIVE STRESS AND APPLICATIONS THEREOF | AIFM2, AIFM1, FECH | FFAR4 1958/4885FFAR1 3395/4885TSHR 1534/4885 |
| US-20250090541-A1 | Methods for Treating Neurodegenerative Disorders | HTT, SNCA, NLN | FFAR4 4469/4885FFAR1 4077/4885TSHR 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.